Sign inJoin waitlistJoin the waitlist

TP

Tycel Phillips

Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation · City of Hope National Medical Center

Credentials: · · · · · · ·

History

City of Hope National Medical Center
Present
City of Hope National Medical Center
Present
City of Hope National Medical Center
Present

Hematology and Medical Oncology
Case Western Reserve University/University Hospitals Cleveland Medical Center
2009–2012
Internal Medicine
John H. Stroger Jr. Hospital of Cook County
2006–2007
Rush Medical College of Rush University Medical Center
2002–2006

Research

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Journal of Clinical Oncology · 2023 · 506 citations
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
The Lancet Oncology · 2020 · 487 citations
Postibrutinib outcomes in patients with mantle cell lymphoma
Blood · 2016 · 259 citations

AD
Alexey Danilov
17 papers
Ryan Wilcox
17 papers · 5 as a fellow
AH
Alex Herrera
12 papers
MK
Mark Kaminski
11 papers
Geoffrey Shouse
10 papers
Sumana Devata
10 papers · 7 as a fellow
Paolo Caimi
9 papers
Yasmin Karimi
9 papers
JB
John Burke
8 papers
LW
Luhua Wang
8 papers
Manali Kamdar
8 papers
Paul Barr
8 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $222.9K · Beckman Research Institute/City of Hope
1997–2027

Clinical trials

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Not yet recruiting · Phase 1, Phase 2
City of Hope Medical Center
2026–2030
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Recruiting · Phase 1
City of Hope Medical Center
2026–2028
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Principal investigator · Suspended · Phase 1, Phase 2
City of Hope Medical Center
2023–2027
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
Principal investigator · Withdrawn · Phase 2
University of Michigan Rogel Cancer Center
2020–2030